Ocular Q3 2026 Results - OCULAR THERAPEUTIX INC

Financial Performance:

• Ended Q3 2026 with $530.6 million in cash and cash equivalents.
• Current cash runway extends into 2028 based on existing assumptions, excluding full commercialization expenses for X-Paxley.
• No specific quarterly revenue, earnings per share (EPS), or profit margin figures were disclosed as the company remains in pre-commercialization stage.
• No mention of deferred revenue, debt levels, or specific burn rate adjustments beyond general capital discipline.

Guidance and Future Outlook:

• Planned NDA submission for X-Paxley (OTX-TKI) in wet AMD during Q4 2026.
• Regulatory submission supported by SOL1 Week 52 efficacy data, SOL1 and SOLAR Week 52 safety data, and repeat dosing safety data from >300 patients.
• Interim SOLAR safety analysis scheduled for Q4 2026; top-line efficacy results for SOLAR expected in Q1 2028.
• Targeting approval via the 505(b)(2) regulatory pathway, potentially reducing review timelines by up to 60 days compared to traditional 505(b)(1) pathways.
• Management anticipates a "superiority" label for X-Paxley based on SOL1 data.

Business Segments and Product Lines:

• X-Paxley (OTX-TKI): Investigational sustained-release intravitreal agent for wet AMD and non-proliferative diabetic retinopathy (NPDR).
• SOL1: Phase 3 trial demonstrating superiority in vision maintenance over aflibercept 2mg with a single injection; ~75% of patients maintained vision at Week 36, ~67% at Week 52.
• SOLAR: Phase 3 non-inferiority trial vs. aflibercept 2mg q8w; primary endpoint shifted from Week 56 to Week 40 to preserve trial integrity ahead of NDA submission.
• SOLX: Open-label extension study modified to assess 48-week dosing intervals (previously 24-week) to support annual maintenance dosing hypotheses.
• HELIOS 3: Phase 3 trial for NPDR evaluating once-yearly X-Paxley dosing; enrollment progressing.
• Commercial Infrastructure: Payer discussions completed with 100% of top-tier national/regional accounts covering ~84% of commercial lives.

Market and Competitive Landscape:

• X-Paxley is positioned as the only intravitreal sustained-release maintenance agent with positive Phase 3 data in wet AMD.
• Differentiation strategy: X-Paxley intended as long-term maintenance therapy following initial bolus anti-VEGF disease control, rather than direct replacement for all bolus therapies.
• Maintenance therapies constitute >90% of the wet AMD market; frequent bolus dosing leads to >40% patient drop-off in the first year.
• Competitive gap identified following a peer's recent TKI program discontinuation in wet AMD.
• High TKI potency (Excedinib) claimed to be ~100x more potent than Voralinamab against VEGFR2, enabling sustained VEGF suppression.

Risks and Challenges:

• Regulatory uncertainty regarding the final NDA approval and label details, though FDA alignment is stated.
• Clinical trial risk: SOLAR remains masked until Week 96; while confidence is high, the primary endpoint integrity was the primary driver for the recent protocol amendment.
• Market adoption risk: Reliance on physician transition from bolus to maintenance paradigm.
• Safety data dependency: FDA requires >300 patients with 1-year follow-up, which will be provided via SOL1 and SOLAR safety subsets.
• No commercial revenue yet; heavy reliance on cash runway to fund NDA submission and launch preparation.

Management Commentary and Tone:

• Tone is exceptionally confident and optimistic, describing 2026 as a "transformational year."
• Management emphasizes "rock-solid" disease control and durability, citing stringent AI-based dryness metrics (<10 nanoliters fluid).
• Strong emphasis on "trial integrity" and FDA alignment regarding the SOLAR endpoint change.
• Strategic pivot: Added Dr. Riyadh Sharif to the Board for commercial expertise while Dr. Sung-Se Hong retires.
• Confidence in X-Paxley's "superiority label" and potential to set a new standard of care.

Analyst Questions and Answers:

• SOLX Dosing Interval: Management confirmed the shift to 48-week intervals is driven by SOL1 durability data showing >70% of patients remain dry at 9-12 months; aligned with FDA.
• SOLAR Endpoint Change: Clarified that the shift from Week 56 to Week 40 was a proactive measure to ensure patient crossing of the endpoint before the masked safety unmasking, preventing operational bias. The decision was made in alignment with the FDA after a Type C meeting in May.
• Label Expectations: Management expects a superiority label and flexible dosing (every 6-12 months); no definitive label discussions with FDA yet.
• Repeat Dosing Data: FDA will have access to repeat dosing data from all SOL1 and SOLAR patients (>300 total) with at least 1-year follow-up, including data from patients receiving multiple injections in SOL1.
• Safety Interim Analysis: Only safety data (not efficacy) from SOLAR Week 52 will be submitted; SOLAR remains fully masked for efficacy until Week 96.
• Commercial Viability: Management believes the combination of SOL1 (superiority/durability), SOLAR (non-inferiority/repeat dosing), and SOLX (annual dosing) provides sufficient data for physician adoption without needing to wait for SOLAR top-line efficacy.

Other Key Points:

• Clinical Roadmap: Management outlined a potential clinical workflow: 1-3 bolus injections for initial drying, followed by X-Paxley for long-term maintenance.
• Patient Selection: SOLAR excludes patients with early persistent fluid or variability (approx. 20% of screened patients) to ensure a stable population for non-inferiority testing.
• NPDR Opportunity: Over 6.3 million Americans suffer from NPDR with <1% treatment rate; X-Paxley aims to address this significant unmet need.
• Safety Database: NDA submission will include a comprehensive safety database with >300 patients having at least 12 months of follow-up, meeting FDA requirements.
• Strategic Alignment: Emphasizes that recent competitor failures highlight the importance of TKI potency, delivery vehicle (hydrogel), and rigorous patient selection.